We found that in patients with HFpEF and diabetes, sacubitril/valsartan significantly reduced HbA1c compared with valsartan, and that new use of insulin was numerically lower in patients randomized to sacubitril/valsartan than in patients randomized to valsartan. Here, INS is linked to diabetes mellitus.